NWBO Profile
Northwest
Biotherapeutics, Inc. (NWBO) is a biotechnology company that focuses
on developing and commercializing immunotherapy products to treat
cancers. Its lead product candidate is DCVax, which is designed to
stimulate a patient's immune system to attack cancer cells. The
company's DCVax platform technology targets over 20 different types of
solid tumor cancers and has been studied in clinical trials.
NWBO has faced significant challenges and controversies in its
history. In 2013, the company was investigated by the Securities and
Exchange Commission (SEC) over allegations that it had made false and
misleading statements about the effectiveness of its DCVax product. In
2018, the company faced accusations that it had made misleading
statements about a clinical trial for DCVax, which led to an
investigation by the SEC and a lawsuit from shareholders.
Despite these challenges, NWBO has continued to develop and test its
DCVax products. In 2020, the company announced that it had completed
enrollment for a phase III clinical trial for DCVax-L, which is
designed to treat glioblastoma, a type of brain cancer. NWBO has also
entered into partnerships with other companies, such as Fraunhofer, to
further develop its technology.
As of March 2023, NWBO's stock
is traded on the OTCQB market and has a market capitalization of
around $40 million. The company's financial performance has been poor,
with losses reported in each of the past five years. It has also faced
delisting threats from Nasdaq due to noncompliance with listing
requirements.
Investors in NWBO should be aware of the
significant risks associated with investing in a company that has a
history of controversy and has struggled to achieve profitability. The
success of NWBO's DCVax products is uncertain, and the company faces
significant competition from other companies developing immunotherapy
treatments for cancer. Additionally, the company's OTCQB listing
status may limit its access to capital and
|
